US Patent Issued to Ultragenyx Pharmaceutical on June 9 for "Gene therapy for treating CDKL5 deficiency disorder" (California, Massachusetts Inventors)

ALEXANDRIA, Va., June 9 -- United States Patent no. 12,649,006, issued on June 9, was assigned to Ultragenyx Pharmaceutical Inc. (Novato, Calif.).

"Gene therapy for treating CDKL5 deficiency disorder" was invented by Sharyl Lynne Fyffe-Maricich (Novato, Calif.), Matthew Scott Fuller (Millis, Mass.), Margaret Caroline Wright (San Rafael, Calif.), Lorelei Ioana Stoica (Acton, Mass.), Stewart Craig (Cambridge, Mass.) and Sean Christopher Daugherty (Petaluma, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "This present disclosure provides adeno-associated viral vectors, recombinant adeno-associated vims (rAAV), and methods of their use in gene therapy for treating CDKL5 deficiency disorder (CDD). Also prov...